These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25427821)

  • 1. Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome.
    Siekmeier R; Hofmann T; Scheuch G; Pokorski M
    Adv Exp Med Biol; 2015; 849():23-38. PubMed ID: 25427821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome.
    Hellström PM; Näslund E; Edholm T; Schmidt PT; Kristensen J; Theodorsson E; Holst JJ; Efendic S
    Neurogastroenterol Motil; 2008 Jun; 20(6):649-59. PubMed ID: 18298441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.
    De León DD; Crutchlow MF; Ham JY; Stoffers DA
    Int J Biochem Cell Biol; 2006; 38(5-6):845-59. PubMed ID: 16202636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1: broadening the incretin concept to involve gut motility.
    Hellström PM
    Regul Pept; 2009 Aug; 156(1-3):9-12. PubMed ID: 19362109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of glucagon-like peptide-1 in the pathogenesis of experimental irritable bowel syndrome rat models.
    Chen Y; Li Z; Yang Y; Lin L; Zhang H
    Int J Mol Med; 2013 Mar; 31(3):607-13. PubMed ID: 23338623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [GLP-1 analogues in treatment of type 1 diabetes mellitus].
    Tölle S
    Dtsch Med Wochenschr; 2014 Oct; 139(42):2123-6. PubMed ID: 25289919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes.
    Marino MT; Costello D; Baughman R; Boss A; Cassidy J; Damico C; van Marle S; van Vliet A; Richardson PC
    Clin Pharmacol Ther; 2010 Aug; 88(2):243-50. PubMed ID: 20592721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.
    Jendle J; Martin SA; Milicevic Z
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1463-74. PubMed ID: 22799463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.
    Gallwitz B
    Diabetes Technol Ther; 2005 Aug; 7(4):651-7. PubMed ID: 16120042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
    Youn YS; Jeon JE; Chae SY; Lee S; Lee KC
    Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer devices and improved formulations of inhaled insulin.
    Rashid J; Absar S; Nahar K; Gupta N; Ahsan F
    Expert Opin Drug Deliv; 2015 Jun; 12(6):917-28. PubMed ID: 25485886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 based therapy for type 2 diabetes.
    Arulmozhi DK; Portha B
    Eur J Pharm Sci; 2006 May; 28(1-2):96-108. PubMed ID: 16488579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled insulin--does it become reality?
    Siekmeier R; Scheuch G
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():81-113. PubMed ID: 19218634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.